AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company's innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Company: |
AlloVir |
||
|
|
||
Headquarters Address: |
139 Main Street |
||
|
Suite 500 |
||
|
Cambridge, MA 02142 |
||
|
|
||
Main Telephone: |
617-433-2605 |
||
|
|
||
Website: |
|||
|
|
||
Ticker/ISIN: |
ALVR(NASDAQ)/US0198181036 |
||
|
|
||
Type of Organization: |
Public |
||
|
|
||
Industry: |
Biotechnology |
||
|
|
||
Key Executives: |
CEO: David Hallal |
||
|
CFO: Vikas Sinha |
||
|
|
||
Investor Relations |
|
||
Contact: |
Medha Chadha |
||
Phone: |
917-765-2125 |
||
Email: |
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005944/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.